New Zealand restricts number of drugs that can undergo priority assessment
This article was originally published in SRA
Executive Summary
New Zealand's drug regulatory authority Medsafe is aiming to cut down on the number of priority assessments it conducts for medicines that address a significant clinical need because it does not have enough resources to deal with the increased number of requests it has received on this front1,2.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.